Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

180.77 -2.16 (-1.18%)
Streaming Delayed Price Updated: 11:40 AM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
71 72 Next >
Blue-Chip Bonanzas: 3 Industry Leaders Trading at Unbelievable Discounts
Thanks to the predictability of big businesses, the bargains found among undervalued blue-chip stocks are simply more trustworthy. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Comparative Study: AbbVie And Industry Competitors In Biotechnology Industry
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,100 Today
Via Benzinga
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Analyst Scoreboard: 6 Ratings For AbbVie
Via Benzinga
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the biosimilar market and prompting calls for regulatory reform to enhance... 
Via Benzinga
AbbVie, Amazon, Goldman Sachs And 2 Major Health Care Stocks On CNBC's 'Final Trades'
AbbVie Inc. has good dividend yield and attractive valuations, according to Jim Lebenthal of Cerity Partners. 
Via Benzinga
AbbVie's Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients
AbbVie announced Phase 2 PICCOLO trial results for Elahere in heavily pre-treated ovarian cancer patients. The trial achieved a 51.9% objective response rate. 
Via Benzinga
Investing in Biotech: High Risk for a Potentially High Reward
Biotech is an exciting and promising area, and investors with some patience, the stomach for volatility, and a high risk tolerance can potentially benefit. 
Via MarketBeat
7 Stocks That Could Safely 10X by 2030
Unlock the potential for exponential growth with these seven 10x stocks that could skyrocket by 2030 if the stars align. 
Via InvestorPlace
Evolus: Chiseling Away At The Aesthetic Market
Via Talk Markets
Hedge Fund Favorites: 7 Stocks to Buy When You’re Feeling Jittery
With the hedge funds targeting certain ideas with their vast resources, retail investors can ride coattails with these stocks to buy. 
Via InvestorPlace
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
If you have the patience and the ability to take a little risk, consider these three biotech stocks to buy since they can really pay off. 
Via InvestorPlace
2 High-Yield Dividend Stocks to Buy Right Now
These two high-yield dividend stocks are top buys right now. 
Via The Motley Fool
The Dividend Dominators: 3 Stocks That Will Make Your Portfolio Reign Supreme
Top dividend stocks across various sectors continue to reward investors, even as they face sales shortfalls and leadership changes. 
Via InvestorPlace
Top Stocks to Buy in June
Here are a few high-quality stocks trading at intriguing valuations. 
Via The Motley Fool
TJX, Sysco, Lululemon And A Healthcare Stock On CNBC's 'Final Trades'
Brenda Vingiello of Sand Hill Global Advisors named TJ Maxx's parent company, The TJX Companies Inc., as her final trade. 
Via Benzinga
7 Overlooked Stocks That Belong in Every Portfolio
Looking beyond the headlines creates an opportunity for investors who have the patience to seek must-own overlooked stocks. 
Via InvestorPlace
3 No-Brainer Stocks to Buy in June
Now is the time to invest in these great stocks. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Generic Drug Makers With Growing Runways
Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
3 Dividend Stocks to Double Up on Right Now
The stories for these great dividend stocks are better than many might think. 
Via The Motley Fool
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
Forget Nvidia, Buy This Magnificent Healthcare Stock Instead
AbbVie's returns haven't been great this year, but investors shouldn't overlook this promising growth stock. 
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These dividend stocks are ideal for investors seeking long-term passive income. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
Via Benzinga
Topics Data Breach
Exposures Information Security
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.